ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis
USA - NASDAQ:ASTH - US03763A2078 - Common Stock
27.77 USD
-2.02 (-6.78%)
27.77 USD
0 (0%)
ASTH gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. ASTH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ASTH is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year ASTH was profitable.
ASTH had a positive operating cash flow in the past year.
ASTH had positive earnings in each of the past 5 years.
In the past 5 years ASTH always reported a positive cash flow from operatings.
1.2 Ratios
ASTH has a Return On Assets (1.75%) which is comparable to the rest of the industry.
ASTH has a Return On Equity of 3.30%. This is comparable to the rest of the industry: ASTH outperforms 57.43% of its industry peers.
With a Return On Invested Capital value of 4.50%, ASTH perfoms like the industry average, outperforming 54.46% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ASTH is below the industry average of 9.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | 3.3% | ||
| ROIC | 4.5% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
1.3 Margins
The Profit Margin of ASTH (1.04%) is comparable to the rest of the industry.
In the last couple of years the Profit Margin of ASTH has declined.
ASTH has a Operating Margin of 2.90%. This is comparable to the rest of the industry: ASTH outperforms 55.45% of its industry peers.
ASTH's Operating Margin has declined in the last couple of years.
ASTH has a worse Gross Margin (11.30%) than 71.29% of its industry peers.
ASTH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.9% | ||
| PM (TTM) | 1.04% | ||
| GM | 11.3% |
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ASTH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ASTH has been increased compared to 1 year ago.
Compared to 1 year ago, ASTH has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.67 indicates that ASTH is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.67, ASTH is in the better half of the industry, outperforming 68.32% of the companies in the same industry.
The Debt to FCF ratio of ASTH is 3.41, which is a good value as it means it would take ASTH, 3.41 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of ASTH (3.41) is better than 75.25% of its industry peers.
A Debt/Equity ratio of 0.52 indicates that ASTH is somewhat dependend on debt financing.
The Debt to Equity ratio of ASTH (0.52) is better than 60.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 3.67 |
ROIC/WACC0.52
WACC8.6%
2.3 Liquidity
ASTH has a Current Ratio of 1.59. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
ASTH's Current ratio of 1.59 is in line compared to the rest of the industry. ASTH outperforms 52.48% of its industry peers.
ASTH has a Quick Ratio of 1.59. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.59, ASTH is in line with its industry, outperforming 56.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.59 |
3. Growth
3.1 Past
ASTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -64.58%.
Measured over the past years, ASTH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 19.19% on average per year.
The Revenue has grown by 51.97% in the past year. This is a very strong growth!
Measured over the past years, ASTH shows a very strong growth in Revenue. The Revenue has been growing by 38.01% on average per year.
EPS 1Y (TTM)-64.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-52.5%
Revenue 1Y (TTM)51.97%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%34.66%
3.2 Future
The Earnings Per Share is expected to grow by 31.87% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 20.51% on average over the next years. This is a very strong growth
EPS Next Y47.59%
EPS Next 2Y52.93%
EPS Next 3Y43.91%
EPS Next 5Y31.87%
Revenue Next Year61.6%
Revenue Next 2Y43.55%
Revenue Next 3Y31.12%
Revenue Next 5Y20.51%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ASTH is valuated quite expensively with a Price/Earnings ratio of 54.45.
The rest of the industry has a similar Price/Earnings ratio as ASTH.
ASTH's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.38.
A Price/Forward Earnings ratio of 13.34 indicates a correct valuation of ASTH.
77.23% of the companies in the same industry are more expensive than ASTH, based on the Price/Forward Earnings ratio.
ASTH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.45 | ||
| Fwd PE | 13.34 |
4.2 Price Multiples
ASTH's Enterprise Value to EBITDA is on the same level as the industry average.
ASTH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ASTH is cheaper than 84.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.44 | ||
| EV/EBITDA | 15.69 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ASTH's earnings are expected to grow with 43.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.14
PEG (5Y)2.84
EPS Next 2Y52.93%
EPS Next 3Y43.91%
5. Dividend
5.1 Amount
No dividends for ASTH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
27.77
-2.02 (-6.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners53.19%
Inst Owner ChangeN/A
Ins Owners9.76%
Ins Owner Change0.39%
Market Cap1.39B
Analysts83.53
Price Target45.9 (65.29%)
Short Float %3.96%
Short Ratio3.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP33.15%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.54%
Min EPS beat(2)-48.7%
Max EPS beat(2)-44.39%
EPS beat(4)1
Avg EPS beat(4)-79.13%
Min EPS beat(4)-225.16%
Max EPS beat(4)1.74%
EPS beat(8)5
Avg EPS beat(8)-25.47%
EPS beat(12)8
Avg EPS beat(12)-7.32%
EPS beat(16)11
Avg EPS beat(16)2.37%
Revenue beat(2)1
Avg Revenue beat(2)-1.49%
Min Revenue beat(2)-3.56%
Max Revenue beat(2)0.57%
Revenue beat(4)3
Avg Revenue beat(4)1.04%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)5.66%
Revenue beat(8)5
Avg Revenue beat(8)0.88%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.15%
PT rev (3m)-10.54%
EPS NQ rev (1m)-4.03%
EPS NQ rev (3m)12.16%
EPS NY rev (1m)7.82%
EPS NY rev (3m)5.16%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)33.01%
Revenue NY rev (1m)10.09%
Revenue NY rev (3m)19.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.45 | ||
| Fwd PE | 13.34 | ||
| P/S | 0.57 | ||
| P/FCF | 11.44 | ||
| P/OCF | 10.62 | ||
| P/B | 1.81 | ||
| P/tB | 5.71 | ||
| EV/EBITDA | 15.69 |
EPS(TTM)0.51
EY1.84%
EPS(NY)2.08
Fwd EY7.5%
FCF(TTM)2.43
FCFY8.74%
OCF(TTM)2.61
OCFY9.42%
SpS48.45
BVpS15.33
TBVpS4.86
PEG (NY)1.14
PEG (5Y)2.84
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.75% | ||
| ROE | 3.3% | ||
| ROCE | 7.13% | ||
| ROIC | 4.5% | ||
| ROICexc | 6.9% | ||
| ROICexgc | 37.52% | ||
| OM | 2.9% | ||
| PM (TTM) | 1.04% | ||
| GM | 11.3% | ||
| FCFM | 5.01% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexcg growth 3Y-13.47%
ROICexcg growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score5
Asset Turnover1.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 4.04 | ||
| Cap/Depr | 31.97% | ||
| Cap/Sales | 0.39% | ||
| Interest Coverage | 8.53 | ||
| Cash Conversion | 131.6% | ||
| Profit Quality | 480.02% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.59 | ||
| Altman-Z | 3.67 |
F-Score5
WACC8.6%
ROIC/WACC0.52
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-64.58%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-52.5%
EPS Next Y47.59%
EPS Next 2Y52.93%
EPS Next 3Y43.91%
EPS Next 5Y31.87%
Revenue 1Y (TTM)51.97%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%34.66%
Revenue Next Year61.6%
Revenue Next 2Y43.55%
Revenue Next 3Y31.12%
Revenue Next 5Y20.51%
EBIT growth 1Y-26.57%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year96.88%
EBIT Next 3Y48.82%
EBIT Next 5Y33.37%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A